Luts & Greenleigh Group Inc. Has $1.05 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Luts & Greenleigh Group Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,274 shares of the company’s stock after selling 402 shares during the quarter. Johnson & Johnson accounts for approximately 1.0% of Luts & Greenleigh Group Inc.’s holdings, making the stock its 22nd biggest position. Luts & Greenleigh Group Inc.’s holdings in Johnson & Johnson were worth $1,052,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Advisory Alpha LLC raised its position in shares of Johnson & Johnson by 7.2% during the fourth quarter. Advisory Alpha LLC now owns 7,216 shares of the company’s stock valued at $1,044,000 after buying an additional 485 shares during the last quarter. Corepath Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 3.7% in the 4th quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock worth $287,000 after acquiring an additional 70 shares during the period. Bourne Lent Asset Management Inc. grew its holdings in shares of Johnson & Johnson by 1.4% during the 4th quarter. Bourne Lent Asset Management Inc. now owns 14,366 shares of the company’s stock worth $2,078,000 after purchasing an additional 200 shares in the last quarter. XML Financial LLC increased its position in shares of Johnson & Johnson by 0.6% during the fourth quarter. XML Financial LLC now owns 69,537 shares of the company’s stock valued at $10,057,000 after purchasing an additional 420 shares during the period. Finally, Genesis Private Wealth LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at $308,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $146.76 on Friday. The firm has a market capitalization of $353.34 billion, a P/E ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.51. The business has a 50-day moving average of $147.99 and a 200-day moving average of $155.98. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22,438,500 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.29 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Activity

In other news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday. Morgan Stanley lowered their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday. Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Finally, Barclays cut their price objective on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a report on Tuesday. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $170.06.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.